CDI Synbiotic Study
The Effectiveness of a Synbiotic Mixture (Inulin, Lactobacillus Rhamnosus (LGG®), Lactobacillus Acidophilus (LA-5®), Lactobacillus Paracasei, and Bifidobacterium Lactis (BB-12®)), on Decreasing Recurrence of Clostridium Difficile Associated Diarrhea- a , Randomized, Placebo-controlled Study With 4 Weeks Intervention
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Andreas M Petersen
- Phone Number: 004538626199
- Email: andreas.munk.petersen@regionh.dk
Study Contact Backup
- Name: Maria IC Rubin
- Email: ingrid.maria.cecilia.rubin@regionh.dk
Study Locations
-
-
-
Hvidovre, Denmark
- Recruiting
- Hvidovre Hospital
-
Contact:
- Andreas M Petersen
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients diagnosed with primary CDI
- Treatment with Vancomycin
- Subjects over 18 years of age
- Signed informed consent
Exclusion Criteria:
- Chemotherapy within two months and an absolute neutrophil count of < 1000 neutrophiles/mm3
- Acute leukemia
- Serious immunodeficiency
- Pancreatitis
- Planned or recent intraabdominal operation within a time window of 14 days
- Terminal disease with expected survival time < 3 month
- Probiotic consumption within two weeks prior enrollment
- Pregnant or lactating women
- A history of inflammatory or irritable bowel disease
- Colectomy and cirrhosis
- Septicemia
- Toxic megacolon
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: probiotic arm
inulin, 15 g Lactobacillus rhamnosus (LGG®) Lactobacillus acidophilus (LA-5®) Lactobacillus paracasei (L.
casei 431®) Bifidobacterium lactis (BB-12®), Total cell counts 150 billion/day
|
A synbiotic mixture consisting of four probiotic strains and inulin (a prebiotic)
|
|
Placebo Comparator: placebo arm
placebo powder, 15 g
|
Placebo powder
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Reduced recurrence of C. difficile-associated diarrhoea (CDAD) after 8 weeks
Time Frame: 1 year
|
telephone questionnaire with patient at end of trial as well as examination of each patient's medical record
|
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
toxin A and B levels measured by qPCR
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Andreas M Petersen, Gastrounit, Hvidovre Hospital
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- H-18041764
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.